Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Sales Rep Survey - Part 2: Drug Makers Exploring Viable Roles amid Govt’s Community-Based Care Initiative
May 6, 2016
- Sales Rep Survey - Part 1: Number of Reps at Foreign Drug Makers Declines Sharply; Down by 330 at GSK
May 2, 2016
- 53 Drug Makers Hire 200 Less New Grads in FY2016, Japan Firms See Hefty Drop: Jiho Tally
April 28, 2016
- Kenji Sukeno to Become New Fujifilm Holdings President
April 28, 2016
- Nogimori to Bow Out as Astellas Chairman
April 28, 2016
- Kaken Licenses Severe Burn Treatment from Israeli Firm
April 27, 2016
- Biogen Eyes Simultaneous Filings in Japan, US, Europe for Alzheimer’s Drug Aducanumab
April 27, 2016
- Harvoni Most Prescribed Drug at Acute Hospitals in October-December
April 27, 2016
- Chugai, Hiroshima Univ. Spinoff Join Hands in Cartilage Regeneration
April 26, 2016
- Boehringer Japan’s Ethical Drug Sales Tick Up 2% in 2015
April 26, 2016
- Novartis Seeks Add’l Indications for Ilaris in Japan
April 26, 2016
- Novartis Looks to Harness Big Data for Indication Expansions: Global Medical Chief
April 26, 2016
- MSD, Sanofi to End RotaTeq, Heptavax Copromotion in Japan
April 25, 2016
- Janssen Files Simponi for Ulcerative Colitis in Japan
April 25, 2016
- Kaketsuken Continues to Suspend Production as Huge Damages Found
April 22, 2016
- Novo Nordisk’s Japan Sales Log Record 89 Billion Yen on Tresiba, Victoza
April 22, 2016
- Around 140 Clinical Trials of Nucleic Acid Drugs Underway Worldwide, with Cancer, Neuropathy, and Myopathy as Main Targets
April 22, 2016
- Mylan Japan Management, Labor Union Remain at Odds over Sales Rep Layoff
April 21, 2016
- Japan’s 1st PCSK9 Inhibitor Hits Market; MHLW Issues Notification to Prevent Hasty Use
April 21, 2016
- Ajinomoto Pulls Out from JV with Yoshindo as EA Pharma Launched
April 21, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…